

Yttrium-90 Radioembolization: Telemedicine during COVID-19 outbreak, opportunity for prime time.

Corresponding and *First* Author:

First name: Lawrence

Middle initial: H H

Last name: Quek

This person is currently NOT in training

Credentials: BMBS (Flinders), MMED, FRCR, FRANZCR

Affiliation: 1, 3

1. Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore

3. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

E-mail: lawrence_quek@ttsh.com.sg

Telephone: +65 6357 8111, Fax: +65 6357 8112

Address: Basement 1, Department of Diagnostic Radiology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433

Co-Author:

First Name: Anbalagan

Last Name: Kannivelu

Credentials: MBBS, MD, DNB, FRCR

Affiliation: 2

2. Department of Diagnostic Radiology, Khoo Teck Puat Hospital

Address: 90 Yishun Central, Singapore 768828

Telephone: +65 6555 8000

e-mail: kannivelu.anbalagan@ktph.com.sg

Co-Author (Last):

First Name: Uei

Last Name: Pua

Credentials: MBBS, MMED, FRCR, FSIR

Affiliation: 1, 4

1. Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore

4. Yong Loo Lin School of Medicine, National University of Singapore, Singapore

e-mail: pua_uei@ttsh.com.sg

Disclaimer : Nil

Word count: 798

No financial support was rendered for this work.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: <https://creativecommons.org/licenses/by/4.0/>.

Details: <http://jnm.snmjournals.org/site/misc/permission.xhtml>.



Yttrium-90 Radioembolization: Telemedicine during COVID-19 outbreak, opportunity for prime time.

TO THE EDITOR:

Telemedicine is broadly defined as use of audiovisual technology in provision of medical care remotely (1). Recent developments in the COVID-19 outbreak necessitated the change of many conventional practices, to avoid cross-infection between healthcare institutions and patients (2). To this end, in Singapore, the movement of doctors between institutions and cross-institutional referral of patients is discouraged, save for absolute essential life-saving services. As such, institutions that are dependent on external (non-inhouse) medical expertise will be impacted, risking non-delivery or suboptimal care to chronic care patients or complex treatment, such as in oncology. To this end, telemedicine can be expounded to bridge the gap in this time of contingency.

Our institution has utilized telemedicine to ensure continuity of care during this crisis in patients requiring Yttrium-90 selective internal radiation therapy (^{90}Y SIRT). ^{90}Y SIRT requires multidisciplinary involvement, including interventional radiologists (IR) for arteriography and nuclear medicine (NM) physicians for both dosimetry and procedural aspects of the therapy which includes verification of the radioactive dose(s) to be administered, setting-up of the delivery system, and administering the dose conjointly with the IR.

In our institution, our NM expertise from an outside institution was prohibited from physically being onsite due to the new restriction. To overcome this, prior to any planning hepatic arteriography and intra-arterial Technetium-99m Macroaggregate Albumin administration (^{99m}Tc -MAA), the case history and recent cross-sectional images were electronically transmitted using secured encrypted channel to the off-site NM physician which will precipitate case discussion, either via secured text messaging or over teleconversation, for suitability of ^{90}Y SIRT as well as the mapping considerations. Hepatic angiographic and scintigraphic images obtained after ^{99m}Tc -MAA administration would be electronically shared for deciding the feasibility and arterial approach, calculation of the perfused territorial volumes, and finalizing the ^{90}Y SIRT dose(s). Similarly, Bremsstrahlung scan images obtained after ^{90}Y implantation would be electronically transmitted for confirming the localization of ^{90}Y microspheres as per the treatment plan. In the procedural room, our unit utilized video conferencing (one with transport encryption) to ensure continuity of the service – the NM physician is “virtually” present to verify the configuration of the delivery system as well as appropriate sites of delivery of the ^{90}Y and monitor radioactive therapy as the IR administers the dose – compliant with our national regulatory authority for radiation protection.

This retrospective study fulfills our institution review board’s requirement for waiver to obtain informed consent. To date, we have treated three cases (all male; mean age, 66 y; range, 57–81 y) successfully without complications. These include two cases of hepatocellular carcinoma (HCC), and a liver dominant colorectal metastatic disease. Radioembolization was performed per standard methodology, delivering a radiation dose of 80–150 Gy to the hepatic parenchyma using glass microspheres (3); both the cases with HCC were treated with an additional boosted

dose to the segment with the largest tumor (range, 6.3 – 9.0 cm) (4). Mean total radiation activity infused was $3.10 \text{ GBq} \pm 1.13$ (median, 2.45 GBq; range, 2.4 – 4.4 GBq). Mean target perfused tissue dose was $129.1 \text{ Gy} \pm 49.1$ (median, 129.5 Gy; range, 72 – 181.3 Gy). The mean number of vials used per treatment was 2. All patients were admitted to the hospital and discharged 1 day after the procedure.

Overall, utilization of telemedicine has allowed our institution to continue collaborating with our off-site NM physician partners in delivery of oncological care to our patients during this outbreak which currently shows no sign of any abatement in the near future. Recognizing the importance of telemedicine, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) provided guidelines for tele-nuclear medicine in interpretation of routine NM studies at a remote location, interpretation of emergency studies in an on-call setting, and consultation (5). This outbreak may spark a wider adoption of tele-nuclear medicine in the post COVID-19 era – not just in diagnosis and therapy but also in education for developing nations with limited access to formal training in NM.

DISCLOSURE

No potential conflicts of interest relevant to this article exist.

Lawrence Quek*

Anbalagan Kannivelu,

Uei Pua

*Tan Tock Seng Hospital

11 Jalan Tan Tock Seng, Singapore 308433

E-mail: lawrence_quek@ttsh.com.sg

References:

1. Kahn JM. Virtual visits – confronting the challenges of telemedicine. *N Engl J Med*. 2015;372(18):1684-5.
2. Czernin J, Fanti S, Herrmann K et al. Imaging clinic operations in the times of COVID-19: Strategies, Precautions and Experiences. *J Nucl Med*. 2020;61(5):1-4. Epub 2020 Apr 1. [Epub ahead of print]
3. Boas FE, Bodei L, Sofocleous CT. Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes. *J Nucl Med*. 2017;58(Suppl 2):104S-111S.
4. Kim HC, Kim YJ, Chung JW et al. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm. *J Vasc Interv Radiol*. 2019;30(1):1-8.
5. Parker JA, Christian P, Wallis JW et al. The SNMMI and EANM practice guideline for tele-nuclear medicine 2.0. *J Nucl Med Technol*. 2014;42(1):15-9.



The Journal of
NUCLEAR MEDICINE

Yttrium-90 Radioembolization: Telemedicine during COVID-19 outbreak, opportunity for prime time.

Lawrence Han Hwee Quek, N.A., Anbalagan Kannivelu and Uei Pua

J Nucl Med.

Published online: April 17, 2020.

Doi: 10.2967/jnumed.120.246389

This article and updated information are available at:

<http://jnm.snmjournals.org/content/early/2020/04/16/jnumed.120.246389.citation>

Information about reproducing figures, tables, or other portions of this article can be found online at:

<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:

<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

JNM ahead of print articles have been peer reviewed and accepted for publication in *JNM*. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the *JNM* ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2020 SNMMI; all rights reserved.